奥斯佩米芬治疗更年期的生殖尿路综合征:患者选择
Giulia Marchetti1, Annika Taithongchai2, Dudley Robinson2
1Urogynaecology Department, Irmandade de Misericórdia da Santa Casa de São Paulo, Sao Paulo, Brazil.
International journal of women's health
|June 10, 2024
概括
奥斯佩米芬为绝经后妇女的部阴道缩提供非激素治疗. 它有效地缓解了阴道干燥和疼痛等症状,特别是对于那些无法使用雌激素治疗的人,包括乳腺癌幸存者.
科学领域:
- 生殖医学 生殖医学
- 妇科 妇科医生 妇科
- 药理学 药理学是指药理学的学科.
背景情况:
- 阴道缩 (VVA) 在绝经后妇女中很普遍,降低了生活质量.
- 症状包括阴道干燥,性交期间的疼痛 (失精症) 和.
- 雌激素治疗是常见的,但对于某些患者来说是禁忌的.
研究的目的:
- 评估Ospemifene作为VVA的非激素治疗方法.
- 突出其有效性和安全性,特别是在高风险人群中.
主要方法:
- 对Ospemifene用于VVA的临床研究的审查.
- 对其作用机制和安全数据的分析.
- 与现有的VVA治疗选择进行比较.
主要成果:
- 奥斯佩米芬在改善阴道干燥和失足症等VVA症状方面表现出有效性.
- 它具有良好的安全性,特别是在乳腺组织方面.
- 对于雌激素治疗有禁忌的女性来说,它是一个合适的替代品.
结论:
- 奥斯佩米芬是一种有价值的非激素治疗选择,用于管理VVA.
- 它为绝经后妇女提供症状缓解和改善生活质量.
- 个性化治疗计划对于优化VVA管理至关重要.
相关概念视频
Menopause
155
Menopause, a natural biological process marking the end of a woman's fertility, typically occurs between the fifth and sixth decade of life. This phase is characterized by the exhaustion of the ovarian follicle pool, leading to less responsive ovaries despite the high levels of Follicle Stimulating Hormone (FSH) and Luteinizing Hormone (LH). The consequential decrease in estrogen production results in symptoms like hot flashes, heavy sweating, headaches, hair loss, muscle pains, vaginal...
155
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
146
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
146
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
153
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
153
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
167
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
167
Antidepressant Drugs: MAOIs and Other Agents
220
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
220
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
194
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
194


